Literature DB >> 25909071

Challenges for molecular diagnosis of familial early-onset diabetes in unexplored populations.

Abdelbasset Amara1, Molka Chadli-Chaieb2, Larbi Chaieb3, Ali Saad4, Moez Gribaa4.   

Abstract

Entities:  

Year:  2014        PMID: 25909071      PMCID: PMC4401046     

Source DB:  PubMed          Journal:  Iran J Public Health        ISSN: 2251-6085            Impact factor:   1.429


× No keyword cloud information.

Dear Editor-in-Chief

Understanding the genetic causes of monogenic forms of diabetes is important for prognostic, follow up, and treatment of the patients (1). MODY (Maturity-onset diabetes of the young) is a form of monogenic diabetes clinically and genetically heterogeneous. Indeed, to-date there are at least 13 different forms of MODY, each one is due to mutations in a specific gene (MODY1-HNF4A, MODY2-GCK, MODY3-HNF1A, MODY4-IPF1, MODY5-HNF1B, MODY6-NEUROD1, MODY7-KLF11, MODY8-CEL, MODY9-PAX4, MODY10-INS, MODY11-BLK, MODY12-ABCC8 and MODY13-KCNJ11) (2). Besides, MODY is not due to a recurrent mutation (1). Molecular diagnosis of MODY is often based on mutation screening using Sanger sequencing and MLPA (Multiplex ligation-dependent probe amplification) (3). In the Tunisian population and in other populations, the genetic causes of familial early-onset diabetes remain unknown (3). In this report, we described the difficulties encountered in determining MODY genetic etiologies, after a mutation screening of PAX4(Paired box gene 4) gene insix MODY-X Tunisian families, using classical methods and suggesting some solutions. The studied families had been previously found negative for mutations and deletions in GCK, HNF1A, HNF4A, HNF1B, INS, IPF1 and NEUROD1 genes (3). The molecular analysis was carried out after taking informed written consent from all patients and after approval of the local ethics committee. We chose to sequence PAX4 gene because of the resemblance between the clinical characteristics of the six families’ probands (Table 1) and the reported MODY9-PAX4 patients (4, 5). Moreover, PAX4 gene encodes a transcription factor which is part of the regulatory mechanism balancing the development of pancreatic beta cells (6).
Table 1

The clinical and molecular characteristics of Tunisian patients selected for PAX4 mutation screening and MODY9 patients of other studies

StudyPatientAge at diagnosticDiabetic generationsBMI Kg/m2Glycaemia mmol/lHbA1c %TraitementPAX4 SNPsConsequence
Our studyF216325,314,112.8INSrs327516rs2233579rs712701c.-221G>Cc.412+35G>Ap.H321P
F427223,56,26INSrs327516c.-221G>C
F524322,810,66.6OHA->INSrs327516rs2233579rs712701c.-221G>Cc.412+35G>Ap.H321P
F62931812,214.9Diet->INSrs327516rs712701c.-221G>Cp.H321P
F826237,212,111.3OHA->INS+OHArs327516rs2233578rs2233579c.-221G>Cp.R133Wc.412+35G>A
F1522323,598.2INSrs327516rs712701c.-221G>Cp.H321P
Thai study(4)Proband202------OHA--p.R164W
Japanese study(5)Proband father153022183235--14.5--INSDiet--c.374-412del39
The sequencing of all nine exons of PAX4 showed four common polymorphisms and nocausal mutations (Table 1). Thus, the six families were negative for an eighth gene out of thirteen (reported to be responsible for MODY forms). The familial early-onset diabetes observed in these patients could be explained by mutations in other reported genes (ABCC8, KCNJ11…) or in unknown genes. This clearly shows the difficulty and time consuming to determine the molecular causes behind MODY-X using Sanger sequencing based on clinical findings. Hence, the need for fast and less expensive techniques that screen all 13 known MODY genes in one step. PCR enrichment in microdroplets combined with next generation sequencing, or targeted next generation sequencing assay could be used as a first step in the research of mutations in known MODY genes (7, 8). In case of mutation absence in these genes, whole exome and genome sequencing combined with high-throughput genotyping and linkage analysis could be useful to identify new genes responsible for monogenic diabetes (2). Otherwise, setting up a research strategy based on metabolomics and biomarkers might be of great interest for molecular diagnostic of MODY. The genetic etiologies of familial early-onset diabetes are still unidentified in many populations. Undeniably, introducing a next generation sequencing-based strategy will reduce costs, increase the throughput, allow gaining precious time and elucidate new pathways underlying the pathophysiology of the disease. The clinical and molecular characteristics of Tunisian patients selected for PAX4 mutation screening and MODY9 patients of other studies
  8 in total

1.  PAX4 mutations in Thais with maturity onset diabetes of the young.

Authors:  Nattachet Plengvidhya; Suwattanee Kooptiwut; Napat Songtawee; Asako Doi; Hiroto Furuta; Masahiro Nishi; Kishio Nanjo; Wiwit Tantibhedhyangkul; Watip Boonyasrisawat; Pa-thai Yenchitsomanus; Alessandro Doria; Napatawn Banchuin
Journal:  J Clin Endocrinol Metab       Date:  2007-04-10       Impact factor: 5.958

2.  A novel PAX4 mutation in a Japanese patient with maturity-onset diabetes of the young.

Authors:  Wakako Jo; Machiko Endo; Katura Ishizu; Akie Nakamura; Toshihiro Tajima
Journal:  Tohoku J Exp Med       Date:  2011-02       Impact factor: 1.848

3.  Familial early-onset diabetes is not a typical MODY in several Tunisian patients.

Authors:  Abdelbasset Amara; Molka Chadli-Chaieb; Hela Ghezaiel; Julien Philippe; Rim Brahem; Aurelie Dechaume; Ali Saad; Larbi Chaieb; Philippe Froguel; Philippe Froguele; Moez Gribaa; Martine Vaxillaire
Journal:  Tunis Med       Date:  2012-12

Review 4.  Promoting ectopic pancreatic fates: pancreas development and future diabetes therapies.

Authors:  E J Pearl; M E Horb
Journal:  Clin Genet       Date:  2008-09-09       Impact factor: 4.438

Review 5.  Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes.

Authors:  Martine Vaxillaire; Philippe Froguel
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

6.  Whole-exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene.

Authors:  Amélie Bonnefond; Julien Philippe; Emmanuelle Durand; Aurélie Dechaume; Marlène Huyvaert; Louise Montagne; Michel Marre; Beverley Balkau; Isabelle Fajardy; Anne Vambergue; Vincent Vatin; Jérôme Delplanque; David Le Guilcher; Franck De Graeve; Cécile Lecoeur; Olivier Sand; Martine Vaxillaire; Philippe Froguel
Journal:  PLoS One       Date:  2012-06-11       Impact factor: 3.240

7.  Highly sensitive diagnosis of 43 monogenic forms of diabetes or obesity through one-step PCR-based enrichment in combination with next-generation sequencing.

Authors:  Amélie Bonnefond; Julien Philippe; Emmanuelle Durand; Jean Muller; Sadia Saeed; Muhammad Arslan; Rosa Martínez; Franck De Graeve; Véronique Dhennin; Iandry Rabearivelo; Michel Polak; Hélène Cavé; Luis Castaño; Martine Vaxillaire; Jean-Louis Mandel; Olivier Sand; Philippe Froguel
Journal:  Diabetes Care       Date:  2013-09-16       Impact factor: 19.112

8.  Improved genetic testing for monogenic diabetes using targeted next-generation sequencing.

Authors:  S Ellard; H Lango Allen; E De Franco; S E Flanagan; G Hysenaj; K Colclough; J A L Houghton; M Shepherd; A T Hattersley; M N Weedon; R Caswell
Journal:  Diabetologia       Date:  2013-06-15       Impact factor: 10.122

  8 in total
  2 in total

1.  Frequency of HNF4A-P.I463V Variant in the Tunisian North-African Population and Its Relation with Diabetes Mellitus.

Authors:  Abdelbasset Amara; Ilhem Ben Charfeddine; Houda Ghédir; Ons Mamaï; Saloua Jemni-Yacoub; Larbi Chaieb; Ali Saad; Molka Chadli-Chaieb; Moez Gribaa
Journal:  Iran J Public Health       Date:  2015-03       Impact factor: 1.429

Review 2.  Tunisian Maturity-Onset Diabetes of the Young: A Short Review and a New Molecular and Clinical Investigation.

Authors:  Mariam Moalla; Wajdi Safi; Maab Babiker Mansour; Mohamed Hadj Kacem; Mona Mahfood; Mohamed Abid; Thouraya Kammoun; Mongia Hachicha; Mouna Mnif-Feki; Faten Hadj Kacem; Hassen Hadj Kacem
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-29       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.